Private Advisor Group LLC Has $214,000 Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Private Advisor Group LLC lowered its position in shares of Catalent, Inc. (NYSE:CTLT) by 25.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,753 shares of the company’s stock after selling 1,596 shares during the quarter. Private Advisor Group LLC’s holdings in Catalent were worth $214,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CTLT. Thompson Siegel & Walmsley LLC raised its position in shares of Catalent by 46.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company’s stock worth $32,069,000 after purchasing an additional 223,944 shares during the period. Vanguard Group Inc. lifted its stake in Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after buying an additional 365,648 shares in the last quarter. Tran Capital Management L.P. boosted its holdings in shares of Catalent by 12.2% in the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock valued at $16,258,000 after buying an additional 39,208 shares during the period. Hsbc Holdings PLC increased its position in shares of Catalent by 43.1% during the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after acquiring an additional 58,240 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Catalent by 240.0% during the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after acquiring an additional 28,410 shares during the period.

Catalent Stock Performance

NYSE CTLT opened at $54.82 on Friday. The firm has a market capitalization of $9.92 billion, a P/E ratio of -8.99, a price-to-earnings-growth ratio of 5.86 and a beta of 1.18. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The firm’s fifty day moving average price is $56.02 and its two-hundred day moving average price is $50.72. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $60.20.

Catalent (NYSE:CTLT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. As a group, research analysts anticipate that Catalent, Inc. will post 0.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CTLT shares. StockNews.com started coverage on Catalent in a report on Tuesday, May 21st. They set a “sell” rating for the company. Stephens reissued an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, February 20th. Finally, UBS Group reaffirmed a “neutral” rating and set a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $53.14.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.